Prevalence of multidrug-resistant bacteria in healthcare and community settings in West Africa: systematic review and meta-analysis.

Moustapha Diop, Oumar Bassoum, Abdourahmane Ndong, Fatimata Wone, Ajuamendem Ghogomu Tamouh, Maguette Ndoye, Tracie Youbong, Sokhna Moumy Mback�� Daff��, Romziath Olouwakemi Radji, Mamadou Wagu�� Gueye, Ndeye Aissatou Lakhe, B��caye Fall, Papa Samba Ba, Adama Faye
Author Information
  1. Moustapha Diop: Department of Infectious and Tropical Diseases, Dakar Principal Hospital, Dakar, Senegal. mouztaphandm@gmail.com.
  2. Oumar Bassoum: Health and Development Institute, Cheikh Anta DIOP University, Dakar, Senegal.
  3. Abdourahmane Ndong: Department of Surgery, Saint-Louis Regional Hospital, Gaston Berger University, Saint Louis, Senegal.
  4. Fatimata Wone: Department of Infectious and Tropical Diseases, Dalal Jamm Hospital, Dakar, Senegal.
  5. Ajuamendem Ghogomu Tamouh: Department of Human Resources, Ministry of Public Health, Yaounde, Cameroon.
  6. Maguette Ndoye: Laboratories Federation, Dakar Principal Hospital, Dakar, Senegal.
  7. Tracie Youbong: Department of Infectious and Tropical Diseases, Dakar Principal Hospital, Dakar, Senegal.
  8. Sokhna Moumy Mback�� Daff��: Laboratories Federation, Dakar Principal Hospital, Dakar, Senegal.
  9. Romziath Olouwakemi Radji: Department of Infectious and Tropical Diseases, Dakar Principal Hospital, Dakar, Senegal.
  10. Mamadou Wagu�� Gueye: Laboratories Federation, Dakar Principal Hospital, Dakar, Senegal.
  11. Ndeye Aissatou Lakhe: Department of Infectious and Tropical Diseases, FANN Teaching Hospital, Dakar, Senegal.
  12. B��caye Fall: Laboratories Federation, Dakar Principal Hospital, Dakar, Senegal.
  13. Papa Samba Ba: Department of Infectious and Tropical Diseases, Dakar Principal Hospital, Dakar, Senegal.
  14. Adama Faye: Health and Development Institute, Cheikh Anta DIOP University, Dakar, Senegal.

Abstract

BACKGROUND: Multidrug-resistant (MDR) bacteria are a global health threat, notably in low- and middle-income countries. The aim of this review was to estimate the prevalence of multidrug-resistant bacteria in healthcare and community settings in West Africa.
METHODS: In accordance with PRISMA guidelines, we searched PubMed, CINAHL, African Index Medicus, and other databases for studies published from 2010 onward. Data on MDR bacterial prevalence, study characteristics, and infection types were extracted and analyzed via R software. Subgroup analyses were performed to explore differences in prevalence across infection settings and sample types.
RESULTS: Out of the 5,320 articles identified, 50 studies from 13 West African countries met the inclusion criteria, with the majority from Nigeria (34%) and Ghana (22%). Among the 35,820 bacteria isolated in these studies, gram-negative bacteria (GNB), particularly Escherichia coli and Klebsiella sp., were the most frequently isolated species, accounting for 63.3% of the bacteria. The overall prevalence of MDR bacteria was 59% (95% CI: 48-69%), with significant heterogeneity between studies (I�� = 98%, p���<���0.001). Subgroup analysis revealed a 7% increase in MDR bacteria prevalence from the first five-year period to the last two five-year periods, and a greater prevalence of MDR bacteria in nosocomial infections (65%, 95% CI: 45-81%) than in community-acquired infections (53%, 95% CI: 31-74%). The prevalence of MDR bacteria in mixed infection settings was 58% (95% CI: 44-71%). The MDR prevalence was highest in the urine samples (72%, 95% CI: 57-84%) and superficial skin samples (69%, 95% CI: 29-92%), whereas it was lowest in the nasopharyngeal samples (26%, 95% CI: 21-33%).
CONCLUSION: The high prevalence of MDR bacteria in West Africa underscores the need for strengthened infection control measures, improved surveillance, and stricter antibiotic use policies. Enhanced regional collaboration is essential to mitigate the spread of AMR in both healthcare and community settings.
PROSPERO REGISTRATION NUMBER: CRD42023470363.

Keywords

References

  1. Afr J Bacteriol Res. 2023 Jan-Jun;15(1): [PMID: 38742183]
  2. Tunis Med. 2022 mai;100(5):390-395 [PMID: 36206088]
  3. Turk J Urol. 2018 Jun 05;45(1):48-55 [PMID: 29975632]
  4. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  5. Med Trop Sante Int. 2021 Apr 7;1(2): [PMID: 35586586]
  6. Sci Rep. 2022 Dec 24;12(1):22290 [PMID: 36566323]
  7. Transpl Infect Dis. 2016 Aug;18(4):566-74 [PMID: 27188439]
  8. J Pharm Bioallied Sci. 2016 Jan-Mar;8(1):29-33 [PMID: 26957865]
  9. BMC Infect Dis. 2022 Feb 3;22(1):119 [PMID: 35114948]
  10. BMJ Open. 2023 Dec 30;13(12):e078367 [PMID: 38159961]
  11. Int J Environ Res Public Health. 2022 Sep 16;19(18): [PMID: 36141932]
  12. Antimicrob Resist Infect Control. 2024 Feb 14;13(1):21 [PMID: 38355621]
  13. Int J Antimicrob Agents. 2017 Nov;50(5):629-639 [PMID: 28705671]
  14. Trans R Soc Trop Med Hyg. 2018 Jan 1;112(1):36-42 [PMID: 29538772]
  15. BMC Res Notes. 2023 Oct 31;16(1):301 [PMID: 37907960]
  16. Glob J Health Sci. 2013 Jan 13;5(2):187-99 [PMID: 23445708]
  17. Diseases. 2018 Jul 19;6(3): [PMID: 30029549]
  18. JAC Antimicrob Resist. 2025 Jan 10;7(1):dlae220 [PMID: 39802112]
  19. BMC Microbiol. 2024 Jan 23;24(1):35 [PMID: 38262985]
  20. PLoS One. 2024 Apr 16;19(4):e0302053 [PMID: 38625961]
  21. Sci Rep. 2021 Oct 21;11(1):20814 [PMID: 34675262]
  22. Clin Microbiol Infect. 2012 Mar;18(3):268-81 [PMID: 21793988]
  23. Antimicrob Resist Infect Control. 2014 May 14;3:17 [PMID: 24883183]
  24. Med Sante Trop. 2017 Jun 1;27(2):147-154 [PMID: 28655675]
  25. J Hepatol. 2019 Mar;70(3):398-411 [PMID: 30391380]
  26. Afr J Lab Med. 2021 Mar 23;10(1):1261 [PMID: 33824857]
  27. Niger J Clin Pract. 2021 Aug;24(8):1225-1233 [PMID: 34397035]
  28. Infect Drug Resist. 2019 Jul 11;12:2059-2067 [PMID: 31372013]
  29. BMC Infect Dis. 2014 Dec 20;14:3859 [PMID: 25526763]
  30. Sci Rep. 2022 Dec 21;12(1):22069 [PMID: 36543904]
  31. Syst Rev. 2015 Jan 01;4:1 [PMID: 25554246]
  32. BMC Infect Dis. 2025 Feb 5;25(1):170 [PMID: 39910483]
  33. Ann Ib Postgrad Med. 2018 Dec;16(2):162-169 [PMID: 31217775]
  34. BMC Infect Dis. 2016 Oct 24;16(1):598 [PMID: 27776490]
  35. PLoS One. 2016 Oct 24;11(10):e0165242 [PMID: 27776162]
  36. Ann Clin Microbiol Antimicrob. 2020 Nov 25;19(1):54 [PMID: 33239061]
  37. Saudi J Kidney Dis Transpl. 2012 Nov;23(6):1320-30 [PMID: 23168877]
  38. Pan Afr Med J. 2017 Feb 02;26:60 [PMID: 28451037]
  39. BMC Infect Dis. 2023 Oct 25;23(1):723 [PMID: 37880663]
  40. PLoS One. 2014 Jan 21;9(1):e85973 [PMID: 24465819]
  41. PLOS Glob Public Health. 2022 Dec 28;2(12):e0000644 [PMID: 36962754]
  42. PLoS One. 2024 Aug 26;19(8):e0309418 [PMID: 39186717]
  43. Int J Environ Res Public Health. 2022 Apr 16;19(8): [PMID: 35457729]
  44. BMC Infect Dis. 2024 Feb 22;24(1):246 [PMID: 38389071]
  45. Dtsch Arztebl Int. 2024 Mar 22;121(6):175-181 [PMID: 38221865]
  46. J Pathog. 2021 Mar 04;2021:6648247 [PMID: 33747569]
  47. J Infect Prev. 2023 Mar;24(2):71-76 [PMID: 36815059]
  48. Syst Rev. 2016 Dec 5;5(1):210 [PMID: 27919275]
  49. Ther Adv Infect Dis. 2022 Dec 7;9:20499361221135128 [PMID: 36518726]
  50. Antimicrob Resist Infect Control. 2022 Nov 8;11(1):134 [PMID: 36348431]
  51. Prim Care. 2018 Sep;45(3):467-484 [PMID: 30115335]
  52. Afr J Infect Dis. 2018 Jun 18;12(2):14-20 [PMID: 30109281]
  53. Front Microbiol. 2022 May 19;13:894319 [PMID: 35663873]
  54. Microbiol Insights. 2022 Jun 24;15:11786361221106109 [PMID: 35769634]
  55. JAC Antimicrob Resist. 2024 Oct 30;6(5):dlae175 [PMID: 39478985]
  56. East Afr Med J. 2013 Dec;90(12):380-6 [PMID: 26848497]
  57. Antibiotics (Basel). 2021 Oct 10;10(10): [PMID: 34680812]
  58. Trop Med Int Health. 2021 Oct;26(10):1220-1230 [PMID: 34185935]
  59. BMC Infect Dis. 2020 Jan 30;20(1):86 [PMID: 32000722]
  60. Niger J Clin Pract. 2024 Jan 1;27(1):35-46 [PMID: 38317033]
  61. Infect Drug Resist. 2023 Jan 26;16:569-579 [PMID: 36726386]
  62. Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S310-6 [PMID: 26449946]
  63. J Glob Antimicrob Resist. 2021 Sep;26:133-139 [PMID: 34129993]
  64. BMC Microbiol. 2022 Oct 11;22(1):245 [PMID: 36221074]
  65. BMC Infect Dis. 2023 Aug 22;23(1):546 [PMID: 37605140]
  66. Nat Clim Chang. 2018 Jun;8(6):510-514 [PMID: 30369964]
  67. Microorganisms. 2023 Jan 12;11(1): [PMID: 36677486]
  68. J Crit Care. 2016 Aug;34:116-20 [PMID: 27288622]
  69. Int J Environ Res Public Health. 2022 Dec 09;19(24): [PMID: 36554436]

MeSH Term

Humans
Drug Resistance, Multiple, Bacterial
Prevalence
Africa, Western
Bacterial Infections
Anti-Bacterial Agents
Cross Infection
Community-Acquired Infections
Bacteria

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0bacteriaMDRprevalence95%CI:settingsWeststudiesinfectionhealthcarecommunityAfricasamplescountriesreviewmultidrug-resistantAfricantypesSubgroupisolatedfive-yearinfectionsPrevalenceBACKGROUND:Multidrug-resistantglobalhealththreatnotablylow-middle-incomeaimestimateMETHODS:accordancePRISMAguidelinessearchedPubMedCINAHLIndexMedicusdatabasespublished2010onwardDatabacterialstudycharacteristicsextractedanalyzedviaRsoftwareanalysesperformedexploredifferencesacrosssampleRESULTS:5320articlesidentified5013metinclusioncriteriamajorityNigeria34%Ghana22%Among35820gram-negativeGNBparticularlyEscherichiacoliKlebsiellaspfrequentlyspeciesaccounting633%overall59%48-69%significantheterogeneityI��=98%p���<���0001analysisrevealed7%increasefirstperiodlasttwoperiodsgreaternosocomial65%45-81%community-acquired53%31-74%mixed58%44-71%highesturine72%57-84%superficialskin69%29-92%whereaslowestnasopharyngeal26%21-33%CONCLUSION:highunderscoresneedstrengthenedcontrolmeasuresimprovedsurveillancestricterantibioticusepoliciesEnhancedregionalcollaborationessentialmitigatespreadAMRPROSPEROREGISTRATIONNUMBER:CRD42023470363Africa:systematicmeta-analysis

Similar Articles

Cited By

No available data.